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ABSTRACT
Korea is an endemic area for hepatitis B virus (HBV) infection. Reactivation of HBV is a well-recognized
complication in patients with chronic HBV infection undergoing cytotoxic or immunosuppressive therapy, and
there are some reports of hepatitis B reverse seroconversion after HSCT. This study evaluated changes in HBV
serology after HSCT. We reviewed the medical records of 141 patients who had available HBV serologic data
after autologous HSCT. Patient information was retrospectively collected from the BMT database. Before
transplantation, 12 patients were positive for hepatitis B surface antigen (HBsAg) and received lamivudine
prophylaxis. There was 1 case of reactivation of HBV among these patients. One hundred twenty-nine patients
were negative for HBsAg before HSCT, of whom 110 were positive and 19 were negative for hepatitis B surface
antibody (anti-HBs). Sixty-two of the 110 patients who were positive for anti-HBs were also positive for
hepatitis B core antibody (anti-HBc). Eight patients were negative for anti-HBs and anti-HBc. Seven patients
who were initially negative for HBsAg were identified as positive after HSCT, and 5 of those 7 patients
developed acute hepatitis, thus indicating reverse seroconversion. Univariate analysis showed that reverse
seroconversions were observed more frequently with multiple myeloma than another disease (P .005; relative
risk, 11.854; 95% confidence interval, 1.381-101.770). Other factors, such as age, sex, and presence of HBcAb
before HSCT, had no statistically significant affect on reverse seroconversion. In conclusion, reverse serocon-
version of HBV is not a rare complication of autologous HSCT, and the risk of reverse seroconversion after
treatment is a serious concern due to possible complications arising from patients’ suppressed immune
systems.
© 2007 American Society for Blood and Marrow Transplantation
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aNTRODUCTION
HSCT is performed worldwide to treat various
iseases, mainly hematologic malignancies. Intensive
hemotherapy and immunosuppression in patients
ho undergo HSCT can result in immune dysfunc-
ion and these patients are at risk for various infec-
ions, including viruses. The risk of fatal hepatitis B
irus (HBV) disease has been reported to be as high Hs 12% after allogeneic transplantation [1,2]. Allo-
eneic HSC transplants from donors with HBV
arries a high risk of HBV infection [1], and because
f the immunocompromised state of recipients of
llogeneic or autologous HSC transplants, HBV
eactivation has become a major hepatic complica-
ion of HSCT in patients with hepatitis B surface
ntigen (HBsAg), especially in areas of prevalent
BV infection [3-6].
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J. E. Uhm et al.464Korea has been an area of the world to which
BV infection is endemic. Although the prevalence of
BsAg has been decreasing since the 1980s because of
accination, a national health and nutrition survey in
998 reported that the seropositivity of HBsAg in
orea was 5.1% (95% conﬁdence interval, 4.5%-
.7%) in males and 4.1% (95% conﬁdence interval,
.6%-4.6%) in females [7].
There have been several reports of reverse sero-
onversion/HBV reactivation in patients previously
ositive for hepatitis B surface antibody (anti-HBs)
fter allogeneic or autologous HSCT [3-6,8-11]. How-
ver, the risk of reverse seroconversion after HSCT,
specially autologous HSCT, has not been well estab-
ished.
In the present study, we conducted a review of
erologic HBV status of patients before and after au-
ologous HSCT and the analyzed risk factors for HBV
eactivation and reverse seroconversion.
ETHODS
atients
Two-hundred ﬁfty-one autologous HSCTs were
erformed in the Department of Medicine, Samsung
edical Center (Seoul, Korea) between March 1996
nd December 2005. Serologic markers of HBV were
ested before and after autologous HSCT, and the
resence of HBsAg and anti-HBs was validated before
ransplantation in all patients. HBV markers of 141 of
51 patients could be veriﬁed after transplantation,
nd we analyzed serologic changes in hepatitis B and
emographics of these 141 patients with post-trans-
lantation HBV markers. We retrospectively re-
iewed their medical records and the BMT database.
epatitis B Markers
We conﬁrmed the hepatitis B infection of all pa-
ients before proceeding with autologous HSCT, in
ccordance with pretransplantation protocol. HBsAg,
nti-HBs, and hepatitis B core antibody (anti-HBc)
ere tested routinely as indicators of HBV infection.
ll patients enrolled in the present study, except for 4
atients who underwent autologous HSCT before the
urrent transplantation protocol, were completely
haracterized for pretransplantation status of HBsAg,
nti-HBs, and anti-HBc. These 4 patients were not
xcluded from the analysis because their pretransplan-
ation status for HBsAg and anti-HBs were available.
atients with HBsAg also were tested for HBeAg and
nti-HBe, and the titer of quantitative HBV DNA
sed the Digene Hybrid Capture 2 (Digene Corpora-
ion, Gaithersburg, Md, USA) assay before and after
ransplantation [12] and were followed up every 3 mo.
ssessment of changes in HBsAg and anti-HBs of
atients without pretransplantation HBsAg was usu- slly accomplished within 1 yr, at which time the vac-
ination was started.
mmunosuppressive Agents
In present study, patients did not have to receive
mmunosuppressive agents such as cyclosporine A or
acrolimus for GVHD prophylaxis during and after
utologous HSCT. However, some patients with mul-
iple myeloma underwent maintenance treatment of
halidomide and dexamethasone therapy. Oral medi-
ation of thalidomide 200 mg was taken daily and
examethasone 40 mg/d was administered orally or
.v. from day 1 to day 4. The next cycle started 29 d
rom the starting date of dexamethasone of the previ-
us cycle.
efinitions
Hepatitis was deﬁned as a serum alanine amino-
ransferase level 100 IU/mL on 2 consecutive deter-
inations 5 d apart [13]. HBV reactivation of pa-
ients positive for HBsAg before transplantation was
eﬁned as an increase in titer of serum HBV DNA [6],
nd reverse seroconversion was deﬁned as appearance
f HBsAg and disappearance of anti-HBs after HSCT
n patients who had no HBsAg but did have anti-HBs
r anti-HBc before transplantation [5,11].
tatistical Analysis
Relative risks for changes in HBV markers were
alculated by the Pearson chi-square test or Fisher
xact test. Multivariate analyses were performed by
ogistic regression. P .05 was considered statistically
igniﬁcant.
ESULTS
atient Characteristics
Patients’ baseline characteristics are presented in
able 1. Median follow-up duration after HSCT was
8.6 mo (range, 1.7-113.9 mo), and median time of
rst follow-up testing for HBV markers was 12 mo
range, 1-63 mo). The median patient age at time of
SCT was 45 yr (range, 16-74 yr) and the numbers of
emales and males were similar (72 versus 69 patients).
atients with multiple myeloma comprised the most
ommon subgroup (53 patients, 38%).
Nineteen of 54 patients with multiple myeloma
eceived thalidomide and dexamethasone therapy after
utologous transplantation for maintenance treat-
ent, and only 3 of 19 patients actually developed
everse seroconversion.
hanges in HBV Serologic Markers
Pretransplantation surveillance of HBV infection
howed that 12 patients (9%) had HBsAg. The num-
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Hepatitis B Markers after Autologous HSCT 465er of patients with anti-HBs was 110 (78%). Eight
atients (5%) had neither anti-HBs nor anti-HBc
Table 2).
All patients with pretransplantation HBsAg re-
eived prophylactic doses of lamivudine at 100 mg/d
efore HSCT. Liver function test results for these
atients were normalized before the start of the con-
itioning regimen. At the time of HSCT, 4 patients
33% of 12 patients positive for HBsAg) had HBV
NA in the blood (median, 47.3 pg/mL; range, 9.8-
40.0 pg/mL). After HSCT, we tested for HBV DNA
ith a quantitative assay every 3 mo. Two patients
howed a loss of HBV DNA to nondetectable levels,
nd 1 patient still had HBV DNA without an increase
n titer. HBV reactivation developed in 1 patient, in
hom post-transplantation HBV DNA increased in
iter within 3 mo from 47.3 to 317.8 pg/mL. Liver
unction in this case remained within the normal
ange during and after transplantation and the HBV
NA titer decreased to a nondetectable range by the
ext follow-up visit without additional treatment with
amivudine.
Among the 129 patients without pretransplanta-
ion HBsAg, 7 patients (5%) became HBsAg positive
nd anti-HBs negative after transplantation (Figure 1)
nd thus represented cases of reverse seroconversion.
ll of these patients had pretransplantation anti-HBs
r anti-HBc. The median patient age in these cases
as 55 yr (range, 44-74 yr), and 6 cases were multiple
yeloma. Four were male and 3 were female. The
edian interval between HSCT and ﬁrst HBV
arker follow-up was 11 mo (range, 4-34 mo). Five of
developed acute hepatitis and 2 showed no abnormal
iver function test results. Median time for acute hep-
titis in 5 patients was 10 mo (range, 4-17 mo) after
able 1. Baseline Characteristics of Patients Who Received Autologous
SCT
Characteristics No. of Patients (%)
otal 141 (100)
ge, median (range) 45 (1674)
ale/female 69 (49)/72 (51)
iagnosis
Acute leukemia 38 (27)
Malignant lymphoma 37 (26)
Multiple myeloma 53 (38)
Solid tumors 13 (9)
onditioning regimen
BEAM 32 (23)
Bucy 5 (3)
VCT 38 (27)
Melphalan 53 (38)
Others 13 (9)
EAM indicates combination therapy of carmustine, etoposide,
cytarabine, and melphalan; BuCy, combination therapy of
busulfan and cyclophosphamide; VCT, combination therapy of
etoposide, cyclophosphamide, and TBI.utologous HSCT and median HBV DNA titer of 7 Catients in reverse seroconversion was 526.2 pg/mL
range, 58.4-654.1 pg/mL). All 7 patients had HBeAg
hen reverse seroconversion occurred and 1 patient
lso had anti-HBe. All patients with reverse serocon-
ersion were treated by lamivudine 100 mg/d. Six
atients had normalized liver function test results,
nti-HBe without HBeAg, and undetectable HBV
NA titer after treatment with lamivudine therapy for
mo. One patient who had HBeAg without anti-HBe
nd high titer of HBV DNA despite lamivudine ther-
py continued lamivudine therapy for 16 mo.
In addition to reverse seroconversion, loss of anti-
Bs, which is a protective antibody against HBV
nfection, was observed in 37 patients (29%). Twelve
f 37 patients had multiple myeloma and 12 of 37
atients had malignant lymphoma. In addition, 9 pa-
ients had acute leukemia and 4 had solid tumor.
Analyses for risk factors for reverse seroconversion
ere performed, and older age (45 yr) and multiple
yeloma emerged as leading risk factors. Multiple
yeloma achieved statistical signiﬁcance as a risk fac-
or for reverse seroconversion as determined through
ultivariate analysis by logistic regression. However,
of 19 patients with multiple myeloma who received
aintenance therapy after autologous transplantation
ctually developed reverse seroconversion and this
oes not have statistical signiﬁcance (P .691; Table 3).
owever, no risk factor could be found for the loss of
nti-HBs.
ISCUSSION
In the current analysis, the frequency of pretrans-
lantation HBsAg positivity was determined to be 9%
95% conﬁdence interval, 4.3%13.7%). All but 1
atient positive for HBsAg before transplantation
ere able to undergo autologous HSCT without
BV reactivation while maintained on lamivudine
rophylaxis. Seven of 129 patients (5%) developed
everse seroconversion, which presented as acute hep-
titis in 5 patients. Moreover, a post-transplantation
able 2. Hepatitis B Markers before HSCT (n  141 Patients)
HBsAg Anti-HBs Anti-HBc
No. of
Patients (%) 95% CI
ositive Negative Positive 12 (9) 4.3-13.7
egative Positive Positive 62 (44)
Negative 45 (32)
Unknown 3 (2)
Subtotal 110 (78) 71.2-84.8
Negative Positive 10 (7)
Negative 8 (5)
Unknown 1 (1)
Subtotal 19 (13) 7.4-18.6I indicates conﬁdence interval.
s
h
s
1
p
1
s
1
l
d
a
H
p
H
m
t
p
a
u
i
a
H
r
H
t
a
p
a
l
c
e
l
a
c
w
H
a
p
H
t
s
n
t
l
u
v
a
1
H
i
o
T
A
M
M
P
P
C
Ag and
J. E. Uhm et al.466urvey of HBV markers showed anti-HBs loss with
igh frequency (37 of 110 patients, 34%).
HBV infection is endemic to Korea, with 7%-9%
eropositivity for HBsAg within the population in the
980s [7]. Although HBsAg seropositivity was re-
orted as only 5.8% in males and 4.4% in females in
998, the prevalence of HBsAg in South Korea is
till much higher than in the United States (0.1%-
%) [6,7].
In clinical practice, patients with various hemato-
ogic and oncologic diseases have often become can-
idates for HSCT, and patients with HBsAg have had
n increased risk for hepatic complications such as
BV reactivation related to HSCT or immunosup-
ressive chemotherapy [2,3,5,8-10,14,15]. Therefore,
BV reactivation and reverse seroconversion of HBV
ay play important roles in the morbidity and mor-
ality of HSCT-related hepatic complications in HBV
revalent areas [5,6,14,15].
There are currently 2 different methods for man-
ging HBV reactivation in HBsAg-positive patients
ndergoing autologous HSCT: (i) deferred therapy,
n which HBsAg-positive patients are treated with
nti-HBV therapy only when there is evidence of
BV virologic reactivation or hepatitis due to HBV
eactivation and (ii) preemptive therapy in which
BsAg-positive patients are started on anti-HBV
herapy at the time of initiation of conditioning ther-
able 3. Risk Factors for Reverse Seroconversion after Autologous HSC
Risk Factor Relative Risk L
ge >45 yr 6.410
ale 1.527
ultiple myeloma 12.154
retransplantation anti-HBs 1.010
retransplantation anti-HBc 1.903
Figure 1. Changes in status of HBsI indicates conﬁdence interval.py [1,6]. Our center has treated all HbsAg-positive
atients in a preemptive manner before autologous or
llogeneic HSCT.
There are several reports describing effective
amivudine prophylaxis in HBsAg-positive patients re-
eiving chemotherapy or HSCT [1,2,13,16-24]. Hsiao
t al [13] reported 12% viral breakthrough during
amivudine therapy (median, 73 wk; range, 19-153 wk)
dministered to HBsAg-positive HSC transplant re-
ipients. Although lamivudine-resistant mutations
ere detected in 10% of these patients, there was no
BV reactivation-related mortality or fulminant hep-
titis [13]. In the present study, only 1 of 12 patients
ositive for HBsAg before transplantation developed
BV reactivation, and this was without acute hepati-
is. Although the causes of viral breakthrough and
pontaneous resolution were unclear, and there were
o available data on mutations or lamivudine resis-
ance; these results might also suggest an efﬁcacy of
amivudine prophylaxis in HBsAg-positive patients
ndergoing HSCT.
Many investigators have reported reverse serocon-
ersion, appearance of HBsAg, and disappearance of
nti-HBs after allogeneic or autologous HSCT [3,5,8-
1,25]. Onozawa et al [11] followed up on the anti-
Bs titer of the 14 allogeneic HSC transplant recip-
ents who had pretransplantation anti-HBs. They
bserved a decreased titer of anti-HBs in all patients
95% CI P
Upper Univariate Multivariate
55.555 0.060 0.054
7.124 0.437 0.588
104.493 0.009 0.005
8.920 0.735 0.993
10.208 0.364 0.446
anti-HBs after autologous HSCT.T
ower
1.334
0.327
1.414
0.114
0.355
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Hepatitis B Markers after Autologous HSCT 467fter transplantation and 5 cases of reverse serocon-
ersion [11]. Dhedin et al [10] reported 4 cases of
everse seroconversion in 37 patients after allogeneic
SCT. Onset of hepatitis due to reverse seroconver-
ion after HSCT has been reported to occur at 6-52
o [8,11,25]. Goyama et al [15] reviewed 16 reverse
eroconversion cases related to HSCT. Five of 16
ases developed in a median time of 13 mo (range,
-22 mo) after autologous HSCT [5].
In the present analysis, reverse seroconversion de-
eloped in 7 of 129 patients who had pretransplantai-
on anti-HBs or anti-HBc but not pretransplantation
BsAg. Four patients had anti-HBs and anti-HBc
efore HSCT and 2 patients had only pretransplan-
ation anti-HBs. One patient with reverse seroconver-
ion had pretransplantation anti-HBc without anti-
Bs. Because of lack of information about previous
accinations, we cannot exclude the possibility of new
nfection of HBV in the 2 patients with reverse sero-
onversion and pretransplantation anti-HBs.
Five of 7 patients with reverse seroconversion pre-
ented with acute hepatitis after autologous HSCT. In
nivariate analysis, multiple myeloma was revealed as
risk factor. Tur-Kaspa et al [26] considered the use
f corticosteroid to be responsible for reverse sero-
onversion. However, there was no statistical correla-
ion between reverse seroconversion and thalidomide-
examethasone maintenance therapy in patients with
ultiple myeloma. Another plausible explanation that
ay account for risk of reverse seroconversion due to
ultiple myeloma is dysfunction of humoral immu-
ity. In the case of allogeneic HSCT, reverse sero-
onversion hepatitis is caused by the loss of recipient-
erived IgG and naive donor immunity against HBV
11,27]. However, further investigations are needed to
lucidate the pathogenesis of reverse seroconversion
fter autologous HSCT.
In addition to reverse seroconversion, loss of anti-
Bs was observed in 37 of 110 patients who had
retransplantation anti-HBs. This result is consistent
ith reports by Onozawa et al [11] that demonstrated
rogressively decreasing titers of anti-HBs after allo-
eneic HSCT. They also reported that disappearance
f anti-HBs occurred 0-18 mo (median, 1 mo) before
he occurrence of reverse seroconversion (range, 12-51
o; median, 20 mo) [11]. However, it was not deter-
ined whether loss of anti-HBs occurs in advance of
BV-related acute hepatitis after HSCT [11].
In conclusion, reverse seroconversion of HBV is
ot a rare complication of autologous HSCT, and loss
f anti-HBs is frequently observed after autologous
SCT. Therefore, it is critical to pay close attention
o the twin possibilities of anti-HBs loss and reverse
eroconversion in cases where patients have anti-HBs
efore autologous HSCT. Further, the sequence of
vents for HBV hepatitis and reverse seroconversion
eeds to be validated, and discussion is needed regard-ng the appropriate scheduling of follow-up testing for
epatic enzymes and HBV serology after HSCT.
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